Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
The median overall survival (mOS) was 25.0 months in the first-line group of patients treated with ONCOS-102 plus chemotherapy, compared with 13.5 months mOS for the chemotherapy-only control groupOslo, Norway, 20 December 2021 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS of 25.0 months for treatment with ONCOS-102 in combination with Standard of Care (SoC) chemotherapy in malignant pleural mesothelioma (MPM) in the subgroup of patients receiving therapy in the first-line setting.